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Abstract  
Background 
The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has 
provided unprecedented insights into the oncogenic features modulating drug response. A 
recent study screened for the response of a thousand human cancer cell lines to a wide 
collection of anti-cancer drugs and illuminated the link between cellular genotypes and 
vulnerability. However, due to essential differences between cell lines and tumors, to date 
the translation into predicting drug response in tumors remains challenging. Recently, 
advances in deep neural networks (DNNs) have revolutionized bioinformatics and 
introduced new techniques to the integration of genomic data. Its application on 
pharmacogenomics may fill the gap between genomics and drug response and improve the 
prediction of drug response in tumors.  
Results 
We proposed a DNN model to predict drug response based on mutation and expression 
profiles of a cancer cell or a tumor. The model contains three subnetworks, i) a mutation 
encoder pre-trained using a large pan-cancer dataset to abstract core representations of 
high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response 
predictor network integrating the first two subnetworks. Given a pair of mutation and 
expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the 
model on a dataset of 622 cancer cell lines and achieved an overall prediction performance 
of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in 
prediction error or stability than two classical methods (linear regression and support vector 
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machine) and four analog DNNs of our model, including DNNs built without TCGA pre-
training, partly replaced by principal components, and built on individual types of input 
data. We then applied the model to predict drug response of 9,059 tumors of 33 cancer 
types. Using per-cancer and pan-cancer settings, the model predicted both known, 
including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast 
cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The 
comprehensive analysis further revealed the molecular mechanisms underlying the 
resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer 
potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. 
Conclusions 
Here we present, as far as we know, the first DNN model to translate pharmacogenomics 
features identified from in vitro drug screening to predict the response of tumors. The 
results covered both well-studied and novel mechanisms of drug resistance and drug targets. 
Our model and findings improve the prediction of drug response and the identification of 
novel therapeutic options. 
Keywords: deep neural networks, pharmacogenomics, drug response prediction, Cancer 
Cell Line Encyclopedia, Genomics of Drug Sensitivity in Cancer, The Cancer Genome 
Atlas  
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Background  
Due to tumor heterogeneity and intra-tumor sub-clones, an accurate prediction of drug 
response and an identification of novel anti-cancer drugs remain challenging tasks [1, 2]. 
Pharmacogenomics, an emerging field studying how genomic alterations and 
transcriptomic programming determine drug response, represents a potential solution [3, 
4]. For instance, recent reports identified mutation profiles associated with drug response 
both in tumor type-specific and pan-cancer manners [5, 6]. As drug response data of large 
patient cohorts are scarcely available, large-scale cell line-based screening can greatly 
facilitate the study of pharmacogenomics in cancer. Recently, the Genomics of Drug 
Sensitivity in Cancer (GDSC) Project proposed a comprehensively landscape of drug 
response of ~1,000 human cancer cell lines to 265 anti-cancer drugs and unveiled crucial 
oncogenic aberrations related to drug sensitivity [7, 8]. Because of the fundamental 
differences between in vitro and in vivo biological systems, a translation of 
pharmacogenomics features derived from cells to the prediction of drug response of tumors 
is to our knowledge not yet realized. 
Deep learning (DL) is the state-of-the-art machine learning technology for learning 
knowledge from complex data and making accurate predictions. It features the ability to 
learn the representation of data without the need for prior knowledge and an assumption 
on data distributions. The DL technology has been successfully applied to bioinformatics 
studies of regulatory genomics, such as predicting binding motifs [9], investigating DNA 
variants [10], deciphering single-cell omics [11, 12], and extraction of genomics features 
for survival prediction [13]. In pharmaceutical and pharmacogenomics research, reports 
have shown its ability to predict drug-target interactions [14], screen for novel anti-cancer 
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drugs [15], and predict drug synergy [16]. Nevertheless, data complexity and the 
requirement of large training datasets have limited its application to integrate genomics 
data and comprehensively predict drug response, hindering the translation to precision 
oncology. 
Addressing the unmet demands, the present study is aimed to predict the response of 
tumors to anti-cancer drugs based on genomic profiles. We designed a deep neural network 
(DNN) model to learn the genetic background from high-dimensional mutation and 
expression profiles using the huge collection of tumors of The Cancer Genome Atlas 
(TCGA). The model was further trained by the pharmacogenomics data developed in 
human cancer cell lines by the GDSC Project and their corresponding genomic and 
transcriptomic alteration, and finally applied to TCGA data again to predict drug response 
of tumors. Collectively, this study demonstrated a novel DL model that bridges cell line-
based pharmacogenomics knowledge via tumor genomic and transcriptomic abstraction to 
predict tumors’ response to compound treatment.  
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Methods 
Datasets 
We downloaded gene-level expression data of 935 cell lines of the Cancer Cell Line 
Encyclopedia (CCLE) and 11,078 TCGA pan-cancer tumors from the CTD2 Data Portal 
[17] and UCSC TumorMap [18], respectively. Given the total numbers of cell lines, tumors, 
and genes as C, T, G, respectively, we metricized the expression data by !""#! =%&'( )*+,,.//01 + 1 , where )*+,,.//01 is the number of transcripts per million of gene g 
(' ∈ 1, 5 ) in cell line c ( 6 ∈ 1, 7 ), and  !8"9: = %&'( )*+,,;</=> + 1 , where )*+,,;</=> denotes the number of transcripts per million of the same gene in tumor t () ∈1, ? ). Genes with low information burden (mean < 1 or st. dev. < 0.5) among TCGA 
samples were removed. Mutation Annotation Format (MAF) files of mutation data were 
downloaded directly from CCLE (1,463 cells) [19, 20] and TCGA databases (10,166 
tumors). Here we only considered four types of nonsynonymous mutations, including 
missense and nonsense mutations, frameshift insertions and deletions. Thus, we had binary 
matrices of @""#! = +,,.//01  and @8"9: = +,,;</=> , where +,,.//01  and +,,;</=>  are the 
mutation states (1 for mutation and 0 for wildtype) of gene g in c and t, respectively. Genes 
with no mutations in CCLE and TCGA samples were eliminated.  
We also downloaded drug response data of 990 CCLE cell lines to 265 anti-cancer 
drugs measured by the half maximal inhibitory concentration (IC50) from the GDSC Project 
[7]. IC50 were measured in µM and represented in log scale (i.e., A"""#! = %&'BC D6E,.//01 , 
with d denoting the d-th drug and F ∈ 1, G ) and missing data were imputed by a weighted 
mean of IC50 of 5 nearest drugs using R packages VIM and laeken [21, 22]. In this study, 
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we analyzed 622 cell lines with available expression, mutation, and IC50 data and 9,059 
tumors with expression and mutation profiles. 
General settings of DNNs and computation environment 
DNN training in this study were performed using the python library Keras 1.2.2 with 
TensorFlow backend. We used fully (or densely) connected layers for all networks. At a 
neuron j, its output HI is calculated by HI = J KLIMLL + NI   (1) 
, where ML is the output of neuron i at the previous layer of j,  KLI and NI denote the synaptic 
weight and bias, respectively, and J represents an activation function. The notation of all 
neurons at a layer can thus be written as O = J PQ + R . (2) 
During training, synaptic weights and biases are adjusted to minimize a loss function. We 
hereafter refer to the two parameters as synaptic parameters because they represent the 
model and can be used to transfer a learned model to another. In this study, models were 
optimized using the Adam optimizer with a loss function of mean squared error (MSE). 
We used the He’s uniform distribution [23] to initialize autoencoders and the Prediction (P) 
network, while the mutation encoder (Menc) and expression encoder (Eenc) in the complete 
model were initialized by the synaptic parameters learned from the pre-training on TCGA 
data. Neuron activation function was set as rectified linear unit (ReLU) except for the 
output layer of P as linear in order to better fit the distribution of log-scale IC50. 
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Overview of the proposed DNN model 
The proposed DNN model was developed to predict IC50 values based on genomic profiles 
of a cell or a tumor. Given the pair of mutation and expression vectors of sample 
c,	 @""#! : , 6 , !""#! : , 6 , the model predicts a D-length vector of IC50, A"""#! 6 , as 
an output. As shown in Figure 1, the model is composed of three networks: i) a mutation 
encoder (Menc), ii) an expression encoder (Eenc), and iii) a prediction feedforward network 
(P). The first and second components are the encoding parts of two autoencoders pre-
trained using TCGA data to learn the high-order features of mutation and expression data 
into a lower dimensional representation. The encoded representation of mutation and 
expression profiles were linked into P and the entire model was trained on CCLE data to 
make prediction of IC50 values. Details of our model are described below. 
Pre-training of mutation and expression encoders 
Autoencoder is an unsupervised DL architecture that includes an asymmetric pair of 
encoder and decoder. By minimizing the loss between input and reconstructed (i.e., 
decoded) data, it reduces the dimension of complex data and captures crucial features at 
the bottleneck layer (the layer between encoder and decoder) (Figure 1B, top and bottom 
panels). We pre-trained an autoencoder on each of the TCGA mutation and expression 
datasets to optimize the capability to capture high-order features. To determine the 
optimized architecture, we adopted a hyper-parameter optimization method, namely 
hyperas [24], to select i) number of neurons at the 1st layer (4096, 2048, or 1024), ii) 
number of neurons at the 2nd layer (512, 256, or 128), iii) number of neurons at the 3rd layer 
(the bottleneck layer; 64, 32, or 16), and iv) batch size (128 or 64). Each combination was 
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trained for 20 epochs; the best-performing model was re-run for 100 epochs and the 
synaptic parameters were saved. 
Complete prediction network 
In our complete model, encoders of the two optimized autoencoders, i.e., Menc and Eenc, 
were linked to P to make predictions of IC50 (Figure 1). P is a 5-layer feedforward neural 
network, including the first layer merging output neurons of the two encoders, three fully 
connected layers, and the last layer of d neurons generating IC50 values of d drugs (Figure 
1B, orange box). In the complete model, architecture (number of layers and neurons at each 
layer) of Menc and Eenc were fixed; their synaptic parameters were initialized using the 
parameters obtained from pre-training in TCGA and updated during the training process. 
P was randomly initialized. We trained the entire model using CCLE data, with 80%, 10%, 
and 10% of samples as training, validation, and testing sets, respectively. We note the 
validation dataset was used to update model parameters but to stop the training process 
when the loss in validation set had stopped decreasing for 3 consecutive epochs to avoid 
model overfitting. Performance of the model was evaluated using the testing samples, i.e., UVW A"""#! : , "XYZX , A"""#! : , "XYZX , where "XYZX denotes the test set of cell lines. 
We applied the final model to predict drug response of TCGA tumors. For a tumor t, @8"9: : , ) , !8"9: : , )  was fed into the model and A"8"9: : , )  was calculated. A high 
predicted IC50 indicates an adverse response of a patient to the corresponding drug. 
Comparison to other model designs 
Performance of the complete neural network model was compared to four different DNN 
designs. First, to assess the effect of TCGA pre-training on Menc and Eenc, we randomly 
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initialized both encoders using the He’s uniform distribution and calculated MSE of the 
entire model. Second, dimension reduction of the Menc and Eenc networks was replaced by 
principal component analysis (PCA). Last two models were built without Menc or Eenc to 
study whether they jointly improved the performance. In each iteration, CCLE samples 
were randomly assigned to training (80%), validation (10%), and testing (10%) and each 
model was trained and tested. Performance in terms of the number of consumed epochs 
and MSE in IC50 were summarized and compared across the 100 iterations. We also 
analyzed two classical prediction methods, multivariate linear regression and regularized 
support vector machine (SVM). For each method, top 64 principle components of 
mutations and gene expression were merged to predict IC50 values of all (using linear 
regression) or individual drugs (SVM).  
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Results and Discussion 
Model construction and evaluation in CCLE 
The study is aimed to predict drug response (measured as log-scale IC50 values) using 
genome-wide mutation and expression profiles. We included mutation and expression 
profiles of 622 CCLE cell lines of 25 tissue types and 9,059 TCGA tumors of 33 cancer 
types. After data preprocessing, 18,281 and 15,363 genes with mutation and expression 
data, respectively, available in both CCLE and TCGA samples were analyzed. Log-scale 
IC50 values of all cell lines in response to 265 anti-cancer drugs were collected from the 
GDSC Project [7]. After imputation of missing values, the range of log IC50 was from -9.8 
to 12.8 with a standard deviation of 2.6 (Figure 2A). We designed a DNN model with three 
building blocks: 4-layer Menc and 4-layer Eenc for capturing high-order features and 
reducing dimensions of mutation and expression data, and a 5-layer prediction network P 
integrating the mutational and transcriptomic features to predict IC50 of multiple drugs 
(Figure 1). To make the best use of the large collection of TCGA pan-cancer data, we pre-
trained an autoencoder for each data type and extracted the encoders, Menc (number of 
neurons at each layer, 18,281, 1,024, 256, and 64) and Eenc (15,363, 1,024, 256, and 64), 
to construct our final model (detailed in Methods). Output neurons of the two encoders 
were linked to P (number of neurons at each layer, 64+64, 128, 128, 128, and 265), of 
which the last layer outputs predicted IC50. Architecture of the complete neural networks 
is shown in Figure 1B. 
After pre-training Menc and Eenc components, we trained the entire model using 80% of 
CCLE samples together with a validation set of 10% of samples to avoid overfitting. The 
remaining samples (64 cells; 16,960 cell-drug combinations) were used for testing. The 
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model achieved an overall MSE in IC50 of 1.53, corresponding to 1.48 and 1.98 in 
training/validation and testing data, respectively. Generally, the distribution of predicted 
IC50 was similar to original data (Figure 2A-B), while the two modes of original data 
seemed to be enhanced (highlighted in Figure 2A). In both training/validation and testing 
data, the prediction was highly consistent to the true data in terms of IC50 values (Pearson 
correlation; [\ ) and rank of drugs (Spearman correlation; [] ) of a sample ( [\ ∈0.70,0.96 , [] ∈ 0.62,0.95 , and all P-values < 1.0×10-29; Figure 2C-D). Of note, 
correlations achieved in training/validation and testing samples were highly comparable 
(Figure 2C-D), confirming the performance of our model. 
Performance comparisons to other designs 
To test the stability of our model, we ran 100 training processes each of which training, 
validation, and testing cells were reselected. Overall, the model converged in 14.0 epochs 
(st. dev., 3.5; Table 1) and achieved an MSE of 1.96 in testing samples (st. dev., 0.13; 
Figure 2E and Table 1). We compared the performance to linear regression, SVM, and four 
analog DNNs of our model, including random initialization (identical architecture, but 
without TCGA pre-training of Menc and Eenc), PCA (Menc and Eenc each replaced by top 64 
principal components of mutation and expression data), Menc only (Eenc removed from the 
model), and Eenc only (Menc removed from the model). The two classical methods seemed 
to suffer from high MSE in testing samples (10.24 and 8.92 for linear regression and SVM, 
respectively; Table 1). Our model also outperformed DNNs with random initialization and 
PCA in MSE (difference in medians, 0.34 and 0.48; Figure 2E and Table 1) and stability 
(st. dev. of MSE in testing samples = 0.13, 1.21, and 0.17 for our model, random 
initialization, and PCA, respectively; Figure 2E). While the Eenc-only model achieved 
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similar performance to our model (difference in medians = 0.0042; Figure 2E and Table 
1), the addition of Menc seemed to bring faster convergence (difference in medians = 3; 
Table 1). Our data echoed the biological premise that gene expressions are more directly 
linked to biological functions and thus richer in information burden than mutations. 
Associations of gene mutations to predicted drug response in TCGA – per-cancer 
study 
In search of effective anti-cancer drugs in tumors, we applied the constructed model 
directly to predict the response of 9,059 TCGA samples to the 265 anti-cancer drugs. The 
predicted IC50 values followed a similar distribution to CCLE cells (Figure 2A, blue line). 
Realizing the different nature of cell lines and tumors, we started by examining several 
drugs with well-known target genes. As shown in Figure 3A, breast invasive carcinoma 
(BRCA) with positive estrogen receptor (ER; assessed by immunohistochemistry by 
TCGA) responded to a selective estrogen receptor modulator, tamoxifen, significantly 
better than ER-negative patients (t-test P = 2.3×10-4). Also, two EGFR inhibitors, afatinib 
and gefitinib, achieved better performance in non-small cell lung cancers (NSCLC) with 
mutated EGFR (P = 2.0×10-7 and 6.6×10-3). While the promising results on these well-
characterized drugs showed the applicability of our model to tumors, we noted that the 
magnitude of differences in predicted IC50 levels was modest, underlining the fundamental 
differences between cell lines and tumors. In order to prioritize mutations underlying drug 
response, we systematically analyzed all cancer–mutation–drug combinations and tested 
the significance of differences in IC50 between samples with and without a mutation for 
each cancer. Here only genes with a mutation rate higher than 10% and harbored by at least 
10 patients in a cancer were analyzed. With a stringent criterion of Bonferroni-adjusted t-
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test P < 1.0×10-5, we identified a total of 4,453 significant cancer–mutation–drug 
combinations involving 256 drugs and 169 cancer–mutation combinations (Figure 3B). 
The top three combinations were TP53 mutations in lung adenocarcinoma (LUAD; 
modulating response to 235 drugs), lung squamous cell carcinoma (LUSC; 228 drugs), and 
stomach adenocarcinoma (STAD; 224 drugs) (Table 2). TP53 was one of the most 
frequently mutated and well-studied genes in many cancers. The mutation has been shown 
to be associated with cancer stem cells and resistance functions and thus regulates drug 
resistance [25, 26]. For instance, our data indicated its associations with resistance of a 
PI3Kβ inhibitor, TGX221, in 9 cancers including low-grade glioma (LGG; mean difference 
in IC50 (ΔIC50) = 0.95; P = 2.2×10-109; Figure 3C) and resistance of vinorelbine in BRCA 
(ΔIC50 = 0.68; P = 7.4×10-71; Figure 3C) and 6 other cancers. We also identified gene 
mutations that sensitized tumors to a large number of drugs, such as IDH1 (138 drugs; 
Table 2). IDH1 was the most frequently mutated gene in LGG (77.3% in our data; Table 
2) and known to regulate cell cycle of glioma cells and enhance the response to 
chemotherapy [27]. Our finding agreed with the report and showed that IDH1 mutation 
dramatically reduced IC50 of chemotherapeutic agents, e.g., doxorubicin in LGG (ΔIC50 = 
-0.85; P = 3.6×10-71; Figure 3C).  
Associations of gene mutations to predicted drug response in TCGA – pan-cancer 
study 
We also carried out a study to explore how gene mutations affect drug response in a pan-
cancer setting. The analysis was focused on 11 genes with mutation rates higher than 10% 
across all TCGA samples (Table 3). Using an identical criterion, we identified 2,119 
significant mutation–drug pairs composed of 256 drugs, among which 1,882 (88.8%) and 
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237 (11.2%) were more resistant and sensitive in mutated samples, respectively (Figure 4A 
and Table 3). TP53 (251 drugs), CSMD3 (223), and SYNE1 (218), TTN (206), and RYR2 
(199) were the top drug response-modulating genes (Table 3). Among them, TP53 (9 
sensitive and 242 resistant drugs) and TTN mutations (44 and 162) were associated with 
the most numbers of resistant and sensitive drugs, respectively (Table 3). Thus, we further 
investigated the drug response and their association with status of the 2 genes. Many of the 
drugs with large TP53 mutations-modulated changes in ΔIC50 (|ΔIC50| ≥ 0.7; Figure 4A-B) 
were previously studied in different cancer types by in vitro models. For instance, wildtype 
TP53 is required in the anti-cancer actions of CX-5461 [28, 29] and sorafenib [30] (both P 
of ΔIC50 ~0 in our data; Figure 4B), sensitizes various cancer cells to bortezomib [31] (P 
= 4.4×10-308; Figure 4B), and enhances phenformin-induced growth inhibition and 
apoptosis [32] (P =2.0×10-241; Figure 4B). As for previously less explored TTN mutations, 
the longest gene in human genome known to carry large variations, our data indicated that 
perhaps TNN acts as a marker gene of tumors sensitized to chemotherapeutic agents such 
as vinorelbine (P ~0; Figure 4C) and a potential anti-cancer drug epothilone B (P =2.5×10-
253; Figure 4C). Taken together findings from our per- and pan-cancer studies, we have 
demonstrated the applicability of our model to predict drug response of tumors and ability 
to unveil novel and well-studied genes modulating drug response in cancer. 
Pharmacogenomics analysis of docetaxel and CX-5461 in TCGA 
To unveil the pharmacogenomics landscape of drugs, a comprehensive study of mutation 
and expression profiles associated with resistance of a drug in a pan-cancer setting was 
carried out. Here we took two drugs as demonstrating examples, a widely used 
chemotherapeutic agent docetaxel and a novel anti-cancer drug CX-5461 currently under 
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investigation in several cancers. For each drug, pan-cancer patients predicted to be very 
sensitive and resistant (with IC50 in bottom and top 1%, n = 91 in each group; Figure 5A, 
left panel) were compared for cancer type composition, mutation rates, and differential 
gene expression. Top cancer types of docetaxel-sensitive patients were among esophageal 
carcinoma (ESCA; 25.3%), cervical and endocervical cancer (CESC; 13.2%), and head 
and neck squamous cell carcinoma (HNSC; 9.9%) (Figure 5B, left panel), while top 
resistant patients were mainly liver hepatocellular carcinoma (LIHC; 42.9%), LGG 
(26.4%), and glioblastoma multiforme (GBM; 12.1%) (Figure 5B, left panel). Top 10 gene 
with most changed mutation rates between the two groups of patients are listed in Figure 
5C. On average, each sensitive tumor harbored 2.7 mutations among these genes, much 
higher than 0.51 observed in the resistant group (Figure 5C, left panel), implying tumors 
with higher mutation burdens in crucial genes may be more vulnerable to the treatment. Of 
note, a great majority of the most significantly differentially expressed genes were 
upregulated in sensitive patients (Figure 5C, left panel). We performed functional 
annotation analysis of the top 300 genes in Gene Ontology terms of biological processes 
and molecular functions using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) v6.7 [33, 34]. While we did not observe any cluster of functions 
related to microtubule, through which docetaxel physically binds to the cell and regulate 
the cell cycle [35], these drug sensitivity-related genes were indeed predominantly enriched 
in functions governing the mitotic cell cycle (Table 4). The observation largely reflected 
the nature of the chemotherapeutic agent to target highly proliferative cells and the 
dependence of drug response on the ability to pass cell-cycle checkpoints. In addition to 
docetaxel, we analyzed a novel anti-cancer agent, CX-5461. This inhibitor of ribosomal 
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RNA synthesis has been shown with anti-cancer properties in cancer cells [36, 37] and is 
now under phase I/II clinical trial in solid tumors (NCT number, NCT02719977). In 
hematopoietic malignancies, it was recently shown to outperform standard chemotherapy 
regimen in treating aggressive acute myeloid leukemia (LAML) [29], and its anti-cancer 
effects were dependent on wild-type TP53 [28, 29]. Concordantly, in our data, LAML and 
lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) jointly accounted for 45.1% 
(41.8% and 3.3%) of patients predicted be respond extremely well to CX-5461 (Figure 5A-
B, right panels). Of note, LGG comprised another 48.4% of the sensitive tumors (Figure 
5B, right panel). Nine of the top 10 differentially mutated genes were enriched in the 
resistant group and leaded by TP53 mutations (mutation rate, 95.6% in resistant vs. 13.2% 
in sensitive patients; Figure 5C, right panel), echoing data from our pan-cancer analysis 
(Figure 4A-B) and previous in vitro and in vivo investigations [28, 29]. IDH1 was the only 
gene preferentially mutated in sensitive tumors and largely marked LGG (mutated in 42 of 
44 sensitive LGG; Figure 5C, right panel). DAVID analysis of the top 300 differentially 
expressed genes highlighted differential mechanisms between solid and non-solid tumors, 
such as extracellular matrix and cell motion (Table 5). Altogether, the pharmacogenomics 
analyses revealed well-known resistance mechanisms of docetaxel and shed light on the 
potential of CX-5461 on hematopoietic malignancies and LGG. 
Limitations and future work 
DNN is unquestionably one of the hottest computational breakthroughs in the era of big 
data. Although promising results of our and other studies have demonstrated its ability of 
solving challenging bioinformatic tasks, the method has several fundamental limitations. 
For instance, due to high representational power and model complexity, the method suffers 
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from overfitting and the requirement of large training data. Addressing this, the present 
study adopts a training–validation partition of training data to allow early stopping to the 
training process [38]. Future work may further incorporate dropout and regularization to 
DNNs. Also, by taking advantage of the transferability of neural networks, we used the 
huge volume of TGCA data to equip our model the ability of capturing representations of 
mutation and expression data. Transferring the learned parameters to initialize our model 
virtually increased the sample size of our training data. Our data from 100 iterations of 
model training suggest the stability of performance and insensitivity to the selection of 
training samples. As the availability of more large-scale drug screening data, we expect the 
proposed model to make even more accurate predictions and unveil subtle 
pharmacogenomics features. Furthermore, our model may incorporate additional genomic 
mutation information, such as copy number alterations, into data matrices @8"9:  and @""#!, to enrich the complexity of tumor mutation for model training and further reduce 
the training MSE. Because of the nature of DNNs as black boxes, the interpretability of 
results is typically limited. In this study, by integrating genomics profiles to the predictions, 
we systematically investigated how single gene mutations, as well as the interplay between 
cancer type, mutations, and biological functions, were associated with the predicted drug 
response. With the advances in DNN, several novel methods were recently proposed to 
extract features learned by neural networks, such as network-centric approach [39] and 
decomposition of predicted outputs by backpropagation onto specific input features [40] 
(reviewed in [41]). Future works may incorporate these methods to provide a landscape of 
pharmacogenomics and further reveal novel oncogenic genomics profiles.  
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Conclusions  
This study addresses the need for a translation of pharmacogenomics features identified 
from pre-clinical cell line models to predict drug response of tumors. We developed a DNN 
model capable of extracting representative features of mutations and gene expression, and 
bridging knowledge learned from cancer cell lines and transferring to tumors. We showed 
the reliability of the model and its superior performance than four different methods. 
Applying our model to the TCGA collection of tumors, we identified both well-studied and 
novel resistance mechanisms and drug targets. Overall, the proposed model is widely 
applicable to incorporate other omics data and to study a wider range of drugs, paving the 
way to the realization of precision oncology.   
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Tables 
Table 1  - Performance of our DNNs and other models 
Measurement Model Linear regression SVM 
Random 
initialization PCA 
Eenc 
only 
Menc 
only 
Median MSE 
in testing 
samplesa 
1.96 10.24b 8.92c 2.30 2.44 1.96 3.09 
Median 
number of 
training 
epochsa 
14 -- -- 9 29 17 9.5 
aMedian of 100 shuffles of training, validation, and testing samples 
bResult of one multivariate regression model 
cResults of 265 SVM models, each predicting IC50 for a drug  
 - 27 - 
Table 2  - Top mutations in modulating drug response among individual cancers 
Cancer Gene Mutation rate 
Num. 
modulated 
drugs 
Num. 
sensitive 
drugs 
Num. 
resistant 
drugs 
LUAD TP53 46.1% 235 0 235 
LUSC TP53 75.1% 228 0 228 
STAD TP53 43.3% 224 0 224 
HNSC TP53 66.1% 207 0 207 
COAD TP53 55.7% 197 0 197 
LIHC TP53 27.0% 194 1 193 
BRCA TP53 32.2% 182 7 175 
LGG IDH1 77.3% 159 138 21 
PRAD TP53 10.8% 146 1 145 
KIRC PBRM1 38.0% 142 3 139 
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Table 3  - Top gene mutations modulating pan-cancer drug response 
Gene Mutation rate 
Num. modulated 
drugs 
Num. sensitive 
drugs 
Num. resistant 
drugs 
TP53 34.3% 251 9 242 
CSMD3 12.6% 223 12 211 
SYNE1 11.5% 218 10 208 
TTN 30.2% 206 44 162 
RYR2 11.9% 199 14 185 
USH2A 10.7% 191 12 179 
LRP1B 12.1% 188 19 169 
FLG 11.0% 183 9 174 
MUC16 19.5% 161 51 110 
PCLO 10.5% 155 12 143 
PIK3CA 11.7% 144 45 99 
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Table 4  - Top GO clusters enriched in top 300 differentially expressed genes 
associated with predicted response to docetaxel 
GO ID GO term Num. genes P-value 
Cluster 1 (enrichment score: 10.89) 
GO:0007049 cell cycle 40 1.13×10-10 
GO:0022402 cell cycle process 33 3.51×10-10 
GO:0000279 M phase 32 1.01×10-15 
Cluster 2 (enrichment score: 3.96) 
GO:0000166 nucleotide binding 56 1.95×10
-4 
GO:0032553 ribonucleotide binding 54 2.74×10
-6 
GO:0032555 
purine 
ribonucleotide 
binding 
54 2.74×10-6 
Cluster 3 (enrichment score: 3.45) 
GO:0000278 mitotic cell cycle 26 1.01×10-9 
GO:0051726 regulation of cell cycle 15 8.48×10
-4 
GO:0007346 regulation of mitotic cell cycle 12 3.09×10
-5 
Cluster 4 (enrichment score: 2.47) 
GO:0051327 M phase of meiotic cell cycle 8 9.46×10
-4 
GO:0007126 meiosis 8 9.46×10-4 
GO:0051321 meiotic cell cycle 8 1.07×10-3 
Cluster 5 (enrichment score: 2.07) 
GO:0051276 chromosome organization 13 8.64×10
-2 
GO:0007059 chromosome segregation 6 9.34×10
-3 
GO:0000070 
mitotic sister 
chromatid 
segregation 
5 2.45×10-3 
Each cluster is represented by the largest three GO terms.  
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Table 5  - Top GO clusters enriched in top 300 differentially expressed genes 
associated with predicted response to CX-5461 
GO ID GO term Num. genes P-value 
Cluster 1 (enrichment score: 8.65) 
GO:0043062 
extracellular 
structure 
organization 
17 2.93×10-9 
GO:0030198 
extracellular 
matrix 
organization 
15 4.55×10-10 
GO:0005201 
extracellular 
matrix structural 
constituent 
13 2.64×10-9 
Cluster 2 (enrichment score: 6.13) 
GO:0008544 epidermis development 18 2.35×10
-9 
GO:0007398 ectoderm development 18 7.71×10
-9 
GO:0030855 epithelial cell differentiation 8 4.60×10
-3 
Cluster 3 (enrichment score: 4.23) 
GO:0030199 collagen fibril organization 9 7.34×10
-9 
GO:0032963 collagen metabolic process 6 5.37×10
-5 
GO:0044259 
multicellular 
organismal 
macromolecule 
metabolic process 
6 8.96×10-5 
Cluster 4 (enrichment score: 2.84) 
GO:0006928 cell motion 18 8.22×10-4 
GO:0016477 cell migration 13 9.51×10-4 
GO:0048870 cell motility 13 2.33×10-3 
Cluster 5 (enrichment score: 2.60) 
GO:0060429 epithelium development 12 6.39×10
-4 
GO:0030855 epithelial cell differentiation 8 4.60×10
-3 
GO:0009913 epidermal cell differentiation 6 4.49×10
-3 
Each cluster is represented by the largest three GO terms.  
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Figures 
Figure 1  - Illustration of the proposed neural network model 
(A) Model overview. Mutation and expression data of TCGA (n = 9,059) were used to pre-
train two autoencoders (highlighted in blue and green) to extract data representations. 
Encoders of the autoencoders, namely mutation encoder Menc and expression encoder Eenc, 
were linked to a prediction network (P; denoted in orange) and the entire model (i.e., Menc, 
Eenc, and P) was trained using CCLE data (n = 622, of which 80%, 10%, and 10% used as 
training, validation, and testing, respectively) to predict the response to 265 drugs. (B) 
Architecture of the neural networks. Numbers denote the number of neurons at each layer. 
Figure 2  - Model construction and evaluation using CCLE datasets 
(A) Density plots of true (with missing values), imputed, and predicted IC50 data of CCLE 
and predicted data of TCGA. (B) Heatmaps of imputed and predicted IC50 data of CCLE. 
(C, D) Sample-wise Pearson and Spearman correlation between imputed and predicted IC50 
data of CCLE samples. (E) Mean square errors of our and 4 other DNN-based designs. The 
proposed model was compared to a model with no TCGA pre-training (with encoders 
randomly initialized; abbreviated as Rand Init), with encoders substituted by PCAs, with 
Eenc only (no Menc), and with Menc only (no Eenc). Each model was trained for 100 times, 
each of which CCLE samples were randomly assigned into training, validation, and testing 
sets. 
 - 32 - 
Figure 3  - Associations of gene mutations to predicted drug response in TCGA – 
per-cancer study 
(A) Predicted IC50 of TCGA tumors with known drug targets in a cancer type. Significance 
of ΔIC50 between tumors with and without a gene mutation was assessed by the two-tailed 
t-test. (B) Gene mutations significantly associated with predicted drug response in a cancer 
type. Middle panel, significant mutation–drug pairs in each cancer (with Bonferroni 
adjusted t-test P < 1.0×10-5). Nodes labeled with names are those with extreme significance 
(adjust P < 1.0×10-60) and magnitude of ΔIC50 (|ΔIC50| ≥ 0.5). Top 10 cancer types with the 
largest sample sizes are denoted by node color and shape. (C) Box plots of three mutation–
drug examples in BRCA and LGG. 
Figure 4  - Associations of gene mutations to predicted drug response in TCGA – 
pan-cancer study 
(A) Gene mutations significantly associated with predicted drug response across all TCGA 
samples. Here only the 11 genes with mutation rates larger than 10% were analyzed. Nodes 
labeled with names are those with extreme significance (adjust P < 1.0×10-200) and 
magnitude of ΔIC50 (ΔIC50 ≥ 0.7 or ΔIC50 < 0). (B, C) Examples of drugs modulated by 
TP53 and TTN mutations, respectively. 
Figure 5  - Pharmacogenomics analysis of docetaxel and CX-5461 in TCGA 
(A) Waterfall plot of predicted IC50 for the two drugs across all TCGA samples. Tumors 
with extreme IC50 values (top and bottom 1%) were denoted as the resistant and sensitive 
groups. (B) Cancer type composition of resistant and sensitive samples. Cancer types 
accounted for at least 10% in any group are highlighted in bold and shown in (C). (C) 
Heatmaps of cancer type composition, top differentially mutated genes, and top 
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differentially expressed genes between the two groups. In the expression heatmap, genes 
are normalized and hierarchically clustered, and samples are clustered within each group. 
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